<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082963</url>
  </required_header>
  <id_info>
    <org_study_id>20150757</org_study_id>
    <secondary_id>1R41HL127907-01A1</secondary_id>
    <nct_id>NCT03082963</nct_id>
  </id_info>
  <brief_title>Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation</brief_title>
  <official_title>Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeffrey Goldberger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to test the feasibility of performing real-time&#xD;
      electrogram morphology recurrence (EMR) mapping in patients with persistent atrial&#xD;
      fibrillation (AF) to locate areas of high electrogram morphology recurrence rate. The&#xD;
      Investigator believe that the EMR mapping can be integrated into cardiac mapping and used to&#xD;
      identify potential sites for ablation. Furthermore, this study could help demonstrate the&#xD;
      efficacy of this technology's ability to terminate or slow AF.&#xD;
&#xD;
      The Investigator will test this technology on ten subjects undergoing a second ablation&#xD;
      procedure. The Investigator will map the AF utilizing the EMR to indicate locations of stable&#xD;
      activity and ablate the area. The Investigator believes that the study could produce acute AF&#xD;
      termination or AF cycle length slowing. In addition to testing the real-time electrogram&#xD;
      morphology recurrence mapping, the study would also like to determine the acute effects of&#xD;
      radiofrequency ablation of areas of high recurrence rates and determine long term freedom&#xD;
      from AF following ablation of areas of high recurrence rates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Real-time electrogram morphology recurrence mapping feasibility</measure>
    <time_frame>2 hours</time_frame>
    <description>Obtain multisite MRP map in the right and left atrium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ablation Acute Effects</measure>
    <time_frame>2 hours</time_frame>
    <description>ablation based on MRP map will either terminate atrial fibrillation or slow atrial fibrillation cycle length by at least 15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day post ablation treatment emergent adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>30 days post ablation procedure safety endpoints will be collected categorizing the type of adverse event, severity, and whether the AE/SAE is related to the mapping</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>EMR Feasibility</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrogram Morphology Mapping (EMR)</intervention_name>
    <description>Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium &amp; then the left atrium.</description>
    <arm_group_label>EMR Feasibility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female at least 21 years of age&#xD;
&#xD;
          -  persistent Afib with one prior failed ablation for persistent or long standing&#xD;
             persistent Afib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to sign consent&#xD;
&#xD;
          -  Patients with a life expectancy less than one (1) year&#xD;
&#xD;
          -  Patients with chronic kidney disease with sufficiently low GFR that precludes either&#xD;
             CT angiogram of the heart or contrast MRI study&#xD;
&#xD;
          -  Pregnant women and women that are breast feeding&#xD;
&#xD;
          -  Patients with multiple (2 or more) prior failed ablations&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering&#xD;
             the study or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Mitrani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jeffrey Goldberger</investigator_full_name>
    <investigator_title>Chief, Cardiovascular Division</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

